Renal Function Threshold in First-Line NSCLC: Is Pemetrexed an Option?
A 68-year-old woman with newly diagnosed metastatic non-squamous NSCLC (PD-L1 TPS 30%, no EGFR, ALK, ROS1, or KRAS G12C driver) is planned for carboplatin AUC 6 + pemetrexed 500 mg/m2 + pembrolizumab. Height 160 cm, weight 58 kg, serum creatinine 1.5 mg/dL. Measured eGFR by CKD-EPI is 38 mL/min/1.73 m2; Cockcroft-Gault CrCl calculates to 41 mL/min. She has well-controlled hypertension, no diabetes, ECOG performance status 1, and normal liver function. Her niece did well on 'the same three-drug regimen,' and the patient asks whether the pemetrexed can simply be dose-reduced rather than dropped. Pharmacy has paclitaxel, nab-paclitaxel, and etoposide on formulary, and the institutional pathway permits any platinum doublet plus a checkpoint inhibitor.
1. Is pemetrexed appropriate for this patient? Show how you reconcile the two renal estimates and state your recommendation.
Read the worked answer
No pemetrexed. This is a threshold decision, not a titratable dose.
- Pemetrexed is eliminated largely unchanged by glomerular filtration (~70-90% of a dose recovered in urine in 24 h). Exposure rises steeply as CrCl falls below 60, and below 45 mL/min the risk of grade 3-4 myelosuppression, mucositis, and acute renal failure is unacceptable.
- The Cockcroft-Gault value (41 mL/min) is the number that governs drug dosing. CKD-EPI eGFR is indexed to body surface area and is not validated for chemotherapy thresholds; when the two disagree at a cutoff, use CG.
- Both estimates sit below the 45 mL/min threshold at which labeling advises against pemetrexed, so dose reduction is not a legitimate workaround. Confirm the creatinine is stable (not a reversible AKI) before abandoning the drug; if it were acute and correctable, recheck before final decision.
Recommendation: switch to carboplatin AUC 5-6 + paclitaxel 200 mg/m2 + pembrolizumab q3w (or nab-paclitaxel if neuropathy or steroid premedication is a concern). Tell the patient the 'three-drug regimen' she heard about is the same backbone with one drug substituted, and that the substitution protects her kidneys and bone marrow rather than reducing efficacy.
2. Calculate and justify the carboplatin dose you would enter, including which renal estimate you use and whether you would modify the AUC.
Read the worked answer
Calvert: total dose (mg) = target AUC x (GFR + 25).
- Using CG CrCl 41: AUC 6 -> 6 x 66 = 396 mg; AUC 5 -> 5 x 66 = 330 mg.
- Using CKD-EPI 38: AUC 6 -> 6 x 63 = 378 mg. The 125 mL/min cap is irrelevant here (no capping needed at this renal function).
Which to use: pick one validated estimate and stay consistent across cycles - most institutions use CG CrCl in the Calvert formula (measured nuclear GFR is more accurate but rarely available same-day). Document the method.
AUC selection: carboplatin is ~70% renally cleared, so the same AUC produces higher exposure at CrCl 41 than at CrCl 100. There is no labeled adjustment, but in a patient with CrCl <45 receiving a myelosuppressive doublet, AUC 5 is a defensible de-escalation; if the team elects AUC 6, do so deliberately with close CBC monitoring after cycle 1.
Practical points: round to the nearest 10 mg, recalculate every cycle from the current creatinine (a falling CrCl will otherwise cause cumulative over-exposure), and never dose carboplatin by BSA.
3. Build the monitoring and counseling plan for the regimen you selected, prioritizing what would change management.
Read the worked answer
What must be checked, and why it changes management:
- CBC with differential before every cycle and at day 10-14 of cycle 1; carboplatin + q3w paclitaxel carries roughly 10-15% febrile neutropenia risk - no routine G-CSF, but a prior FN or sustained grade 4 neutropenia would trigger secondary prophylaxis.
- BMP/creatinine every cycle - dose recalculated, not carried forward; also screens for the renal toxicity that made pemetrexed untenable.
- Peripheral neuropathy graded each visit (paclitaxel) - grade 2 sensory neuropathy typically prompts a dose reduction to 135 mg/m2 or a switch to nab-paclitaxel; grade 3 stops it.
- Immune-related toxicity surveillance with pembrolizumab: TSH at baseline and each cycle, and explicit teaching to report diarrhea, new cough/dyspnea, rash, or fatigue immediately - early steroids prevent grade 3-4 irAEs.
Supportive plan: dexamethasone 20 mg PO 12 and 6 hours before paclitaxel plus H1/H2 blockade (or the equivalent institutional premedication); NK1 antagonist + 5-HT3 antagonist + dexamethasone for emetogenicity; hydration; avoid NSAIDs; inactivated influenza/pneumococcal and RSV vaccination (no live vaccines); HSV/VZV prophylaxis only if indicated by local pathway. Reassure that the carboplatin/paclitaxel/pembrolizumab substitution preserves the intent of curative-intent systemic therapy while respecting her renal reserve.